Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keytruda, Opdivo Set To Challenge Tecentriq In Bladder Cancer

Executive Summary

Phase III trial of Merck's Keytruda stops early with survival benefit as FDA accepts filing of Bristol's Opdivo, which has breakthrough therapy status and priority review.

You may also be interested in...



Kalydeco Expands Indication Without Clinical Data; Keytruda Is Latest Bladder Cancer Approval

Keeping track of US FDA approvals last week included watching the creative and the familiar.

PD-1 Sponsors Expand Into Bladder, Head & Neck Cancer

Merck claims first Phase III survival data in bladder cancer for Keytruda, while Bristol shows potential for immunotherapy combinations in bladder and head and neck cancers at the annual SITC meeting.

Keeping Track: Oncology Approvals And Responses To Complete Response Letters

The latest drug development news and highlights from our FDA Performance Tracker.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel